These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 850068)
21. Regulation of myeloma growth in vitro by idiotype-specific T lymphocytes. Flood PM; Philipps C; Taupier MA; Schreiber H J Immunol; 1980 Jan; 124(1):424-30. PubMed ID: 6965296 [TBL] [Abstract][Full Text] [Related]
22. Effect of immune response to sheep red blood cells on plasmacytoma MOPC 104 E. Ghanta VK; Hiramoto NS; Hiramoto RN Cancer Res; 1981 Jun; 41(6):2197-9. PubMed ID: 7237419 [TBL] [Abstract][Full Text] [Related]
23. Lymphocyte surface membrane immunoglobulin in myeloma. II. T cells with IgA-Fc receptors are markedly increased in mice with IgA plasmacytomas. Hoover RG; Lynch RG J Immunol; 1980 Sep; 125(3):1280-8. PubMed ID: 6967897 [TBL] [Abstract][Full Text] [Related]
24. Preparation and properties of an antiplasma cell serum directed against a defined plasmacytoma cell population. Proctor ML; Herscowitz HB J Immunol; 1975 Dec; 115(6):1642-9. PubMed ID: 1184969 [TBL] [Abstract][Full Text] [Related]
25. Diffusible suppressor factor from splenic macrophages in murine plasmacytoma. Chen YH; Heller P Clin Exp Immunol; 1984 Jul; 57(1):171-7. PubMed ID: 6378461 [TBL] [Abstract][Full Text] [Related]
26. Discussion paper: immunosuppression induced in vivo and in vitro by different classes of plasmacytomas. Specter S; Friedman H Ann N Y Acad Sci; 1976; 276():479-87. PubMed ID: 1071972 [No Abstract] [Full Text] [Related]
27. Nonsecretory myeloma: a study on hypoimmunoglobulinemia. Shustik C; Michel R; Karsh J Acta Haematol; 1988; 80(3):153-8. PubMed ID: 2973720 [TBL] [Abstract][Full Text] [Related]
28. Murine IgA binding factors (IgA-BF) suppressing IgA production: characterization and target specificity of IgA-BF. Noro N; Adachi M; Yasuda K; Masuda T; Yodoi J J Immunol; 1986 Apr; 136(8):2910-6. PubMed ID: 3514749 [TBL] [Abstract][Full Text] [Related]
29. In vitro immunoglobulin synthesis by lymphocytes from patients with rheumatoid arthritis. I. Effect of monocyte depletion and demonstration of an increased proportion of lymphocytes forming rosettes with mouse erythrocytes. Plater-Zyberk C; Clarke MF; Lam K; Mumford PA; Room GR; Maini RN Clin Exp Immunol; 1983 Jun; 52(3):505-11. PubMed ID: 6603295 [TBL] [Abstract][Full Text] [Related]
30. Immune dysfunction in mice with plasmacytomas. I. Evidence that transforming growth factor-beta contributes to the altered expression of activation receptors on host B lymphocytes. Berg DJ; Lynch RG J Immunol; 1991 Apr; 146(8):2865-72. PubMed ID: 1826699 [TBL] [Abstract][Full Text] [Related]
31. Role of intracisternal A-particles and of RNA molecules in plasmacytoma-associated immunodeficiency. Katzmann J; Bhoopalam N; Heller P; Hwang LT; Ostro M; Lavelle D; Giacomoni D Cancer Res; 1978 Aug; 38(8):2555-61. PubMed ID: 307429 [TBL] [Abstract][Full Text] [Related]
32. Suppressor T cells in the pathogenesis of hypogammaglobulinemia associated with a thymoma. Waldmann TA; Broder S; Durm M; Blackman M; Krakauer R; Meade B Trans Assoc Am Physicians; 1975; 88():120-34. PubMed ID: 1083579 [TBL] [Abstract][Full Text] [Related]
33. Regulatory function of normal monocytes in the in vitro immunoglobulin production. Pryjma J; Miklaszewska J Arch Immunol Ther Exp (Warsz); 1981; 29(3):331-6. PubMed ID: 6457580 [TBL] [Abstract][Full Text] [Related]
34. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy. Adler A; Keisari Y; Ofir R J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051 [TBL] [Abstract][Full Text] [Related]
35. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. II. Suppression of T-cell cytotoxicity by pretreatment of mice with subimmunogenic doses of tumour cells. Cihak J; Ziegler HW; Kölsch E Immunology; 1981 May; 43(1):145-52. PubMed ID: 6972902 [TBL] [Abstract][Full Text] [Related]
36. Immunosuppression associated with SJL/J murine lymphoma. II. Characterization of a plasma suppressor factor in tumor-bearing mice. Kumar RK; Lykke AW; Penny R J Natl Cancer Inst; 1981 Dec; 67(6):1277-82. PubMed ID: 6947110 [TBL] [Abstract][Full Text] [Related]
37. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells. Tsuchiya Y; Igarashi M; Suzuki R; Kumagai K J Immunol; 1988 Jul; 141(2):699-708. PubMed ID: 2968407 [TBL] [Abstract][Full Text] [Related]
38. Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Fu YX; Watson G; Jimenez JJ; Wang Y; Lopez DM Cancer Res; 1990 Jan; 50(2):227-34. PubMed ID: 2136804 [TBL] [Abstract][Full Text] [Related]
39. Regulation of B cell maturation and differentiation. I. Suppression of pokeweed mitogen-induced B cell differentiation by tumor necrosis factor (TNF). Kashiwa H; Wright SC; Bonavida B J Immunol; 1987 Mar; 138(5):1383-90. PubMed ID: 2949015 [TBL] [Abstract][Full Text] [Related]
40. Accessory cells in immune suppression. II. Evidence for presentation of idiotype-specific suppressor factors to B cell targets by I-A+ accessory cells. Moser G; Kauffman MG; Abbas AK J Immunol; 1985 May; 134(5):2867-71. PubMed ID: 2580003 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]